BIIB

BIOGEN INC.

v3.25.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Total revenue $ 2,431.0 $ 2,290.5
Cost and expenses:    
Cost of sales, excluding amortization and impairment of acquired intangible assets 629.3 542.2
Research and development 434.1 445.4
Acquired in-process research and development, upfront and milestone expense 200.7 7.5
Selling, general and administrative 572.5 581.5
Amortization and impairment of acquired intangible assets 111.8 78.3
Collaboration profit sharing/(loss reimbursement) 58.1 65.6
(Gain) loss on fair value remeasurement of contingent consideration 9.6 0.0
Restructuring charges 35.3 11.5
Other (income) expense, net 68.4 93.7
Total cost and expense 2,119.8 1,825.7
Income before income tax (benefit) expense 311.2 464.8
Income tax (benefit) expense 70.7 71.4
Net income attributable to Biogen Inc. $ 240.5 $ 393.4
Net income per share:    
Basic earnings per share attributable to Biogen Inc. (in USD per share) $ 1.65 $ 2.71
Diluted earnings per share attributable to Biogen Inc. (in USD per share) $ 1.64 $ 2.70
Weighted-average shares used in calculating:    
Basic earnings per share attributable to Biogen Inc. (in USD per share) 146.1 145.2
Diluted earnings per share attributable to Biogen Inc. (in USD per share) 146.6 145.9
Product revenue, net    
Total revenue $ 1,726.5 $ 1,711.9
Revenue from anti-CD20 therapeutic programs    
Total revenue 378.2 394.0
Alzheimer's collaboration revenue    
Total revenue 33.0 2.8
Contract manufacturing, royalty and other revenue    
Total revenue $ 293.3 $ 181.8